JPMorgan lowered the firm’s price target on Sarepta to $202 from $205 and keeps an Overweight rating on the shares. The firm updated models in smid-cap biotechnology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT: